Tenofovir Alafenamide Fumarate Reduces Virological Replication in HBeAg-Negative Patients With Normal Alanine Aminotransferase: A 48-Week Randomised Controlled Trial.

ABSTRACT: The optimal strategy for chronic hepatitis B virus (HBV) infected patients with negative hepatitis B e-antigen (HBeAg) and normal alanine aminotransferase (ALT) remains uncertain. This study aimed to evaluate the safety and efficacy of tenofovir alafenamide fumarate (TAF) treatment in this patient population. This prospective, open-label, randomised controlled trial enrolled HBeAg-negative patients with normal ALT and randomised them 1:1 to either the treatment group (TAF) or the control group (no treatment). The primary endpoint was the reduction in hepatitis B surface antigen (HBsAg) levels from baseline to week 48. A total of 62 patients were enrolled and followed up by 48 weeks (n = 31 per group). No serious adverse events were reported. At week 48, there was no significant difference

SUBMITTER: Luo Q 

PROVIDER: S-EPMC12853233 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature